These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 23946220)

  • 41. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy.
    Tobian AA; Grabowski MK; Serwadda D; Newell K; Ssebbowa P; Franco V; Nalugoda F; Wawer MJ; Gray RH; Quinn TC; Reynolds SJ;
    J Infect Dis; 2013 Sep; 208(5):839-46. PubMed ID: 23812240
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
    Lingappa JR; Baeten JM; Wald A; Hughes JP; Thomas KK; Mujugira A; Mugo N; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Magaret AS; Wang RS; Kidoguchi L; Barnes L; Ridzon R; Corey L; Celum C;
    Lancet; 2010 Mar; 375(9717):824-33. PubMed ID: 20153888
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
    Baeten JM; Lingappa J; Beck I; Frenkel LM; Pepper G; Celum C; Wald A; Fife KH; Were E; Mugo N; Sanchez J; Essex M; Makhema J; Kiarie J; Farquhar C; Corey L
    J Infect Dis; 2011 Jan; 203(1):117-21. PubMed ID: 21148504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
    Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
    Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
    Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Valacyclovir for the treatment of genital herpes.
    Brantley JS; Hicks L; Sra K; Tyring SK
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):367-76. PubMed ID: 16771614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.
    Cowan FM; Pascoe SJ; Barlow KL; Langhaug LF; Jaffar S; Hargrove JW; Robinson NJ; Bassett MT; Wilson D; Brown DW; Hayes RJ
    Sex Transm Infect; 2008 Dec; 84(7):548-53. PubMed ID: 18684855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Time to refocus on HSV interventions for HIV prevention?
    Tanton C; Abu-Raddad LJ; Weiss HA
    J Infect Dis; 2011 Dec; 204(12):1822-6. PubMed ID: 21998480
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.
    Wald A; Selke S; Warren T; Aoki FY; Sacks S; Diaz-Mitoma F; Corey L
    Sex Transm Dis; 2006 Sep; 33(9):529-33. PubMed ID: 16540883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Valacyclovir. New indication: for genital herpes, simpler administration.
    Can Fam Physician; 1999 Jul; 45():1698-700, 1703-5. PubMed ID: 10424269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
    Sheffield JS; Hill JB; Hollier LM; Laibl VR; Roberts SW; Sanchez PJ; Wendel GD
    Obstet Gynecol; 2006 Jul; 108(1):141-7. PubMed ID: 16816068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of safety and efficacy of prolonged suppressive therapy of genital herpes with valacyclovir.
    Durglishvili N; Shishniashvili D; Kvirkvelia V
    Georgian Med News; 2009; (172-173):47-9. PubMed ID: 19644189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of herpes simplex virus type 2 infection, human immunodeficiency virus/herpes simplex virus type 2 coinfection, and associated risk factors in a national, population-based survey in Kenya.
    Mugo N; Dadabhai SS; Bunnell R; Williamson J; Bennett E; Baya I; Akinyi N; Mohamed I; Kaiser R
    Sex Transm Dis; 2011 Nov; 38(11):1059-66. PubMed ID: 21992985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reducing the risk of transmitting genital herpes: advances in understanding and therapy.
    Leone P
    Curr Med Res Opin; 2005 Oct; 21(10):1577-82. PubMed ID: 16238897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.
    Dunne EF; Whitehead S; Sternberg M; Thepamnuay S; Leelawiwat W; McNicholl JM; Sumanapun S; Tappero JW; Siriprapasiri T; Markowitz L
    J Acquir Immune Defic Syndr; 2008 Sep; 49(1):77-83. PubMed ID: 18667923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
    Celum C; Wald A; Lingappa JR; Magaret AS; Wang RS; Mugo N; Mujugira A; Baeten JM; Mullins JI; Hughes JP; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Stevens W; Campbell MS; Thomas KK; Coombs RW; Morrow R; Whittington WL; McElrath MJ; Barnes L; Ridzon R; Corey L;
    N Engl J Med; 2010 Feb; 362(5):427-39. PubMed ID: 20089951
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures.
    Miller CS; Cunningham LL; Lindroth JE; Avdiushko SA
    J Am Dent Assoc; 2004 Sep; 135(9):1311-8. PubMed ID: 15493396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women.
    Andrews WW; Kimberlin DF; Whitley R; Cliver S; Ramsey PS; Deeter R
    Am J Obstet Gynecol; 2006 Mar; 194(3):774-81. PubMed ID: 16522412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
    Drake AL; Roxby AC; Ongecha-Owuor F; Kiarie J; John-Stewart G; Wald A; Richardson BA; Hitti J; Overbaugh J; Emery S; Farquhar C
    J Infect Dis; 2012 Feb; 205(3):366-75. PubMed ID: 22147786
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2.
    Ludema C; Cole SR; Poole C; Chu H; Eron JJ
    AIDS; 2011 Jun; 25(10):1265-9. PubMed ID: 21666542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.